Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Diagnostic technology company's HIV test remains choice of U.S hospitals
February 20th, 2005
MedMira Inc. (TSX Venture: MIR, NASDAQ:MMIRF) announced that the results of the 2004 U.S. Centers for Disease Control and Prevention (CDC) HIV Rapid Testing performance evaluation showed that MedMira's Reveal Rapid HIV-1 Antibody Test (Reveal) remains the test of choice in U.S. hospitals for the second consecutive year. The 2004 CDC study asked participants to evaluate a panel of HIV-positive and negative donor specimens, that were provided by the CDC, using the rapid HIV test utilized at their facility. A total of 384 participating testing sites took part in the study. The study results indicated that the accuracy of the Reveal test with HIV-positive specimens was...
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
